6:48 AM ET
8-K
Clinical Trial Data
Atrium Therapeutics Clinical Trial Data
Atrium Therapeutics announced nonclinical data for its lead therapy ATR 1072 showing reversal of cardiac glycogen accumulation and improvement in hypertrophy in a mouse model of PRKAG2 syndrome. The company plans to present these findings at the American Heart Association Scientific Sessions 2026 and expects initial Phase 1/2 clinical proof-of-concept data in the second half of 2027.